ASH Meeting on Hematologic Malignancies

Coverage of ASH’s newest clinical meeting, featuring top experts in hematologic malignancies discussing the latest developments in clinical care and answering challenging patient care questions.

Hear MHM Co-Chairs Dr. Ken Anderson and Dr. Martin Tallman discuss this year’s meeting in the latest Hematologist podcast.

  • TP53 Mutation Associated With Poor, But Varied, Outcomes in Myelodysplastic Syndromes Saturday, September 17th, 2016 | October 2016, Volume 2, Issue 10

    The TP53 mutation, a common molecular abnormality in myeloid malignancies such as myelodysplastic syndromes (MDS), is associated with poor outcomes; however, it is unclear whether specific characteristics of the mutation can affect prognosis. At the 2016 ASH Meeting on Hematologic Malignancies, Karam Al-Issa, MD, of the Leukemia Program at the Cleveland Clinic in Cleveland, Ohio, […]

  • Studies Examine Link Between Ibrutinib and Atrial Fibrillation in Patients With Leukemia and Lymphoma Saturday, September 17th, 2016 | , ,

    Though drug ibrutinib has been linked to the development of atrial fibrillation (AF) and atrial flutter (AFl), with an observed incidence of AF among patients taking ibrutinib of 6 to 9 percent. Two pooled analyses presented at the 2016 ASH Meeting on Hematologic Malignancies confirm the risk of AF/AFl development with ibrutinib treatment, and highlight […]

  • Improving Risk Stratification in Standard-Risk Myeloma Patients: Age, Bone Marrow Involvement Independently Predict Survival Saturday, September 17th, 2016 | October 2016, Volume 2, Issue 10

    Though the field of multiple myeloma (MM) has seen many advances in treatment in the past two years – including three new drug approvals – patients who have so-called standard-risk cytogenetics often have poor survival outcomes. These poor outcomes indicate that there is still a need for better risk-stratification methods, according to Moritz Binder, MD, […]

  • A Look at Patient Outcomes in Overlapping Multiple Myeloma and Chronic Lymphocytic Leukemia Saturday, September 17th, 2016 | , ,

    Though multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) have overlapping epidemiologic features and originate from mature B cells, the simultaneous occurrence of both cancers is rare, and data on clinical outcomes and the management of these concurrent disease are limited. At the 2016 ASH Meeting on Hematologic Malignancies, Bhagirathbhai Dholaria, MBBS, of the Division […]

  • Adolescents and Minority Groups Underrepresented in Cancer Clinical Trials Saturday, September 17th, 2016 | October 2016, Volume 2, Issue 10

    Adolescent and young adult (AYA) patients, defined as those between the ages of 15 and 29 years, and non-white patients are often under-represented in clinical trials of novel agents in hematologic malignancies, meaning that these patients might not benefit from the therapeutic advances gained through these trials. In two studies presented at the 2016 ASH […]

1 of 3
back to top